HR. 9418In Committee
Access to Innovative Treatments Act of 2026
Require CMS to quickly review certain Medicare drug coverage denials or limits that conflict with FDA approval and stop using inconsistent preapproval determinations
Plain-English overview
What this bill does
Require CMS to quickly review certain Medicare drug coverage denials or limits that conflict with FDA approval and stop using inconsistent preapproval determinations
Key points
- Require CMS review requests
- Prohibit inconsistent preapproval determinations
Current status
Where it stands
Status
In Committee
Latest action
2026-06-24 — Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Related context
Topics and policy areas
undefinedHealth